Pharmacare Funding on the Chopping Block, Health Advocates Warn

Health advocates are sounding the alarm over the future of national pharmacare in Canada, warning that the federal government is signalling no new funding for additional deals with provinces just as the program was beginning to deliver coverage to Canadians. The concern follows the government's Spring Economic Update, which projected no fresh pharmacare money this spring and a decline in bilateral health funding over the coming years, a trajectory that critics say threatens to leave a landmark health initiative unfinished.

What the update signalled

According to the Spring Economic Update, there will be no new federal funding for additional pharmacare agreements in the spring of 2026. At the same time, bilateral health funding is set to drop from $4.3 billion in the 2025-26 fiscal year to $3.1 billion by 2027-28, a reduction that advocates fear will squeeze programs across the health system, pharmacare among them.

The signal has alarmed organisations that fought for years to establish a national pharmacare framework. The Pharmacare Act was passed in 2024, and the federal government subsequently signed bilateral agreements with British Columbia, Manitoba and Prince Edward Island, contributing tens of millions of dollars to support the expansion of public coverage for diabetes medications and contraception. Those early deals were meant to be the foundation of a broader national program.

The worry now is that the program will stall before it can expand to the rest of the country. More than 60 organisations wrote to the federal health minister urging the government to stay committed to pharmacare, warning that it would be unacceptable to let funding lapse just as some Canadians had started to benefit from it.

How pharmacare was supposed to work

National pharmacare has been a long-standing goal of health advocates and a recurring promise in Canadian politics. The idea is to extend public coverage to prescription medications, addressing a gap in the country's otherwise universal health system that leaves many Canadians paying out of pocket for drugs or going without medications they cannot afford.

The model established under the Pharmacare Act began with a focus on diabetes medications and contraception, two categories chosen for their broad impact and their potential to demonstrate the program's value quickly. The bilateral agreements with British Columbia, Manitoba and Prince Edward Island were intended to be the first wave, with other provinces expected to follow as funding and negotiations allowed.

That phased approach always depended on sustained federal funding to bring additional provinces on board. Without new money, the program risks being frozen at its current limited reach, covering a handful of provinces and a narrow set of medications rather than expanding into the national program its proponents envisioned.

The advocates' case

For the organisations pressing the government, the stakes are about more than budget lines. They argue that pharmacare addresses a basic equity problem in Canadian health care: that access to needed medications should not depend on a person's income, employment or province of residence. Letting the program lapse, in their view, would entrench the very inequities it was designed to close.

The advocates have also pointed to the awkward timing. Funding is being questioned just as the first cohorts of Canadians have begun to benefit from expanded coverage of diabetes drugs and contraception. Pulling back at that moment, they argue, would not only halt progress but could undermine public confidence in the government's commitment to the program.

Their letter to the health minister framed the issue in stark terms, calling it unacceptable that the government would signal an intention to let funding lapse just as the benefits were starting to flow. The campaign reflects a broader anxiety among health groups about the direction of federal health funding more generally.

The fiscal context

The government's caution on new spending sits within a difficult fiscal and economic environment. With the economy having stalled and the government juggling competing priorities, including a major defence buildup and an ambitious investment agenda, health advocates are competing for attention and dollars in a crowded field.

The decline in bilateral health funding over the coming years suggests the government is looking to restrain growth in health transfers even as demands on the system rise. That puts pressure not only on pharmacare but on a range of programs that depend on federal-provincial agreements, from mental health to home care.

The government has not framed its position as abandoning pharmacare outright, and the precise path forward remains to be seen. But the absence of new funding commitments has been enough to trigger concern among those who view continued federal investment as essential to keeping the program alive and growing.

What it means for Canadians

For Canadians who rely on diabetes medications or contraception, the early pharmacare agreements have made a tangible difference in provinces that signed on. The uncertainty now hanging over the program raises questions about whether that coverage will be sustained and whether Canadians in other provinces will ever gain access.

More broadly, the debate touches the perennial Canadian question of how far the public health system should extend. Prescription drugs have long been the notable exception to universal coverage, and pharmacare was meant to begin closing that gap. A stall would leave millions of Canadians continuing to navigate a patchwork of private plans, provincial programs and out-of-pocket costs.

The outcome will also signal how the government intends to balance social-program commitments against its broader fiscal and economic priorities. For households watching their medication costs, that balance is far from abstract.

A decades-long debate

The push for national pharmacare is one of the oldest unfinished projects in Canadian social policy. Ever since the country built its universal health system in the decades after the Second World War, advocates have pointed to the absence of prescription drug coverage as a glaring gap, leaving Canada as one of the few countries with universal health care but no comparable national drug plan.

Numerous commissions and expert panels over the years have recommended some form of national pharmacare, only for the proposals to founder on questions of cost, federal-provincial jurisdiction and political will. The passage of the Pharmacare Act in 2024 was hailed by supporters as a historic breakthrough, the moment the long-deferred goal finally began to move from aspiration to reality.

That history is part of why the current funding uncertainty has provoked such a strong reaction. For advocates who have campaigned across generations, the prospect of the program stalling so soon after its launch evokes a familiar pattern of pharmacare being promised, partially delivered and then left incomplete. They fear the country may once again let the goal slip from its grasp.

The federal-provincial tangle

Like much of Canadian health policy, pharmacare is caught in the complex interplay between federal and provincial responsibilities. Health care delivery falls largely under provincial jurisdiction, but the federal government holds significant influence through its spending power, using funding agreements to shape provincial programs. Pharmacare depends on that arrangement working smoothly.

The bilateral model adopted under the Pharmacare Act reflects this reality. Rather than imposing a single national scheme, Ottawa has negotiated agreements province by province, contributing funding in exchange for expanded coverage of specified medications. That approach allows for flexibility but also makes the program's expansion contingent on continued federal money and on the willingness of additional provinces to sign on.

When federal funding is in doubt, the entire structure becomes fragile. Provinces are unlikely to expand coverage without assurance of federal support, and those already participating may hesitate to deepen their commitments. The signal of no new money therefore threatens not just expansion to new provinces but the momentum of the program as a whole, leaving its future hostage to the next round of fiscal decisions.

The cost of inaction

Advocates argue that the costs of failing to expand pharmacare are themselves substantial, even if they are less visible than the price tag of the program. When Canadians cannot afford their medications, they may skip doses, ration prescriptions or forgo treatment altogether, choices that can lead to worse health outcomes and, ultimately, greater costs to the health system through hospitalisations and complications.

Proponents of pharmacare contend that universal coverage of prescription drugs could, over time, generate savings by improving health outcomes and through the bulk purchasing power a national program could wield. From that perspective, the funding under question is less an expense than an investment, one that pays dividends in both health and economic terms.

The focus on diabetes medications and contraception in the program's early phase was chosen partly for those reasons, targeting categories where improved access can have a broad and measurable impact. Stalling the program before it expands, advocates warn, means forgoing those benefits and leaving in place the inequities and inefficiencies that pharmacare was designed to address, a cost they argue the country can ill afford.

What's next

The pressure campaign from health organisations is unlikely to subside, and the government will face continued calls to clarify its intentions and to commit new funding. Provinces that have not yet signed agreements will be watching closely, as will those already participating who depend on continued federal support.

The future of national pharmacare now hinges on choices the government has yet to fully spell out. Whether it recommits to expanding the program or allows it to plateau will shape the lives of Canadians who depend on affordable access to medications, and will stand as a marker of the government's social-policy priorities in a period of fiscal restraint.

For advocates who spent years pushing pharmacare from idea to legislation, the coming months will determine whether that achievement becomes a lasting national program or an unfinished promise.